JP2014510727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510727A5 JP2014510727A5 JP2013557870A JP2013557870A JP2014510727A5 JP 2014510727 A5 JP2014510727 A5 JP 2014510727A5 JP 2013557870 A JP2013557870 A JP 2013557870A JP 2013557870 A JP2013557870 A JP 2013557870A JP 2014510727 A5 JP2014510727 A5 JP 2014510727A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- alkyl
- compound according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- 229910052736 halogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 10
- -1 R 22 is H Chemical compound 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- 102000015303 Fatty Acid Synthases Human genes 0.000 claims description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims description 4
- 230000008482 dysregulation Effects 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- 210000001672 ovary Anatomy 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 201000010453 lymph node cancer Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000011282 treatment Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 0 *C(CC1)(CCN1C(c1cc(C2=*I=C(*)N2)c(*)cc1*)=O)c1cc(*)c(*)c(*)c1 Chemical compound *C(CC1)(CCN1C(c1cc(C2=*I=C(*)N2)c(*)cc1*)=O)c1cc(*)c(*)c(*)c1 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161450482P | 2011-03-08 | 2011-03-08 | |
| US201161450561P | 2011-03-08 | 2011-03-08 | |
| US61/450,482 | 2011-03-08 | ||
| US61/450,561 | 2011-03-08 | ||
| US201161508611P | 2011-07-16 | 2011-07-16 | |
| US61/508,611 | 2011-07-16 | ||
| US201261585642P | 2012-01-11 | 2012-01-11 | |
| US61/585,642 | 2012-01-11 | ||
| PCT/US2012/028309 WO2012122391A1 (en) | 2011-03-08 | 2012-03-08 | Heterocyclic modulators of lipid synthesis |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016018611A Division JP2016074742A (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
| JP2016018610A Division JP6061437B2 (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510727A JP2014510727A (ja) | 2014-05-01 |
| JP2014510727A5 true JP2014510727A5 (enExample) | 2015-04-30 |
| JP5973473B2 JP5973473B2 (ja) | 2016-08-23 |
Family
ID=48221725
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557870A Active JP5973473B2 (ja) | 2011-03-08 | 2012-03-08 | 脂質合成の複素環式モジュレーター |
| JP2016018610A Active JP6061437B2 (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
| JP2016018611A Pending JP2016074742A (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016018610A Active JP6061437B2 (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
| JP2016018611A Pending JP2016074742A (ja) | 2011-03-08 | 2016-02-03 | 脂質合成の複素環式モジュレーター |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP3190108B1 (enExample) |
| JP (3) | JP5973473B2 (enExample) |
| KR (2) | KR101968058B1 (enExample) |
| CN (2) | CN103561576B (enExample) |
| AU (1) | AU2012225390B2 (enExample) |
| BR (3) | BR122015005121B1 (enExample) |
| CA (1) | CA2829082C (enExample) |
| DK (1) | DK2683244T3 (enExample) |
| EA (1) | EA031193B1 (enExample) |
| ES (2) | ES2883274T3 (enExample) |
| HK (1) | HK1216310A1 (enExample) |
| HR (1) | HRP20170500T1 (enExample) |
| HU (1) | HUE032459T2 (enExample) |
| IL (2) | IL228276A (enExample) |
| LT (1) | LT2683244T (enExample) |
| MX (2) | MX369388B (enExample) |
| PL (1) | PL2683244T3 (enExample) |
| PT (1) | PT2683244T (enExample) |
| SI (1) | SI2683244T1 (enExample) |
| WO (1) | WO2012122391A1 (enExample) |
| ZA (1) | ZA201306655B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI522348B (zh) | 2011-03-08 | 2016-02-21 | ３ Ｖ生物科技公司 | 脂質合成之雜環調節劑 |
| US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| US9624173B2 (en) | 2011-03-08 | 2017-04-18 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| KR102071095B1 (ko) | 2012-07-03 | 2020-01-29 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
| AR092211A1 (es) * | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| CA2900309A1 (fr) * | 2013-02-14 | 2014-08-21 | Galderma Research & Development | Procede de synthese de 4-piperidin-4-yl-benzene-1,3-diol et de ses sels et nouveau compose 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle |
| JP6163214B2 (ja) * | 2013-03-06 | 2017-07-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ウイルス化合物 |
| MX364895B (es) * | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| CA2934251C (en) * | 2013-12-20 | 2024-01-02 | 3-V Biosciences, Inc. | A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer |
| JP6522007B2 (ja) * | 2014-01-07 | 2019-05-29 | ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 癌及びウイルス感染症に対する使用のための脂質合成の複素環式モジュレータ |
| CN104774204A (zh) * | 2014-01-15 | 2015-07-15 | 鲁南贝特制药有限公司 | 一种制备奈韦拉平及其中间体的方法 |
| WO2015199206A1 (ja) * | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| ES2833454T3 (es) * | 2014-08-15 | 2021-06-15 | Sagimet Biosciences Inc | Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente |
| JP6758314B2 (ja) * | 2015-03-19 | 2020-09-23 | サギメット バイオサイエンシーズ インコーポレイテッド | 脂質合成の複素環式調節因子 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
| EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| AU2016314621B2 (en) * | 2015-09-04 | 2021-05-13 | Poli Md S.R.L. | Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections |
| KR102644934B1 (ko) * | 2016-11-11 | 2024-03-08 | 새지메트 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
| CN107043347B (zh) * | 2016-11-18 | 2019-07-02 | 泰州禾益新材料科技有限公司 | 一种阿加曲班中间体(2r，4r)-4-甲基哌啶-2-甲酸乙酯的合成方法 |
| CN109212056B (zh) * | 2018-08-19 | 2021-05-07 | 丁立平 | 一种测定水源水中三种痕量单卤代甲基苯甲酸的气相色谱-质谱联用法 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| WO2021229533A1 (en) * | 2020-05-14 | 2021-11-18 | Palani Llc | A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections |
| CN114469945A (zh) * | 2020-10-28 | 2022-05-13 | 歌礼生物科技（杭州）有限公司 | 脂肪酸合酶抑制剂的用途和药物组合物 |
| CN113584044A (zh) * | 2021-08-28 | 2021-11-02 | 青岛农业大学 | 一种牙鲆socs3基因及其真核表达载体、表达系统和异源表达方法 |
| IL319179A (en) * | 2022-10-01 | 2025-04-01 | Assia Chem Ind Ltd | Solid forms of Dinipenstat |
| WO2024240108A1 (zh) * | 2023-05-19 | 2024-11-28 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| KR20260056149A (ko) * | 2023-07-21 | 2026-04-24 | 새지메트 바이오사이언시스, 인코포레이티드 | 헤테로고리 화합물을 함유하는 약제학적 조성물 |
| WO2025086054A1 (zh) * | 2023-10-23 | 2025-05-01 | 歌礼生物科技（杭州）有限公司 | 一种包含苯甲腈衍生物的药物组合物 |
| AU2024395542A1 (en) | 2023-12-07 | 2026-05-28 | Böse Pharmaceuticals Ab | Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| US5376359A (en) | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| KR101363278B1 (ko) * | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 ｌｘｒ 변조제 |
| DE602006011363D1 (de) * | 2005-12-01 | 2010-02-04 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| WO2008059214A1 (en) * | 2006-11-13 | 2008-05-22 | Astrazeneca Ab | Bisamlde derivatives and use thereof as fatty acid synthase inhibitors |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| WO2008075077A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
-
2012
- 2012-03-08 LT LTEP12754969.9T patent/LT2683244T/lt unknown
- 2012-03-08 MX MX2016009579A patent/MX369388B/es unknown
- 2012-03-08 KR KR1020187017297A patent/KR101968058B1/ko active Active
- 2012-03-08 SI SI201230912A patent/SI2683244T1/sl unknown
- 2012-03-08 HU HUE12754969A patent/HUE032459T2/en unknown
- 2012-03-08 PT PT127549699T patent/PT2683244T/pt unknown
- 2012-03-08 AU AU2012225390A patent/AU2012225390B2/en active Active
- 2012-03-08 ES ES17153778T patent/ES2883274T3/es active Active
- 2012-03-08 DK DK12754969.9T patent/DK2683244T3/en active
- 2012-03-08 BR BR122015005121-5A patent/BR122015005121B1/pt active IP Right Grant
- 2012-03-08 BR BR112013022761A patent/BR112013022761B8/pt active IP Right Grant
- 2012-03-08 PL PL12754969T patent/PL2683244T3/pl unknown
- 2012-03-08 CN CN201280020832.9A patent/CN103561576B/zh active Active
- 2012-03-08 CA CA2829082A patent/CA2829082C/en active Active
- 2012-03-08 EP EP17153778.0A patent/EP3190108B1/en active Active
- 2012-03-08 BR BR122015005122-3A patent/BR122015005122B1/pt active IP Right Grant
- 2012-03-08 EA EA201391290A patent/EA031193B1/ru unknown
- 2012-03-08 ES ES12754969.9T patent/ES2624131T3/es active Active
- 2012-03-08 EP EP12754969.9A patent/EP2683244B1/en active Active
- 2012-03-08 WO PCT/US2012/028309 patent/WO2012122391A1/en not_active Ceased
- 2012-03-08 JP JP2013557870A patent/JP5973473B2/ja active Active
- 2012-03-08 HR HRP20170500TT patent/HRP20170500T1/hr unknown
- 2012-03-08 MX MX2013010170A patent/MX342287B/es active IP Right Grant
- 2012-03-08 KR KR1020137026499A patent/KR101930106B1/ko active Active
- 2012-03-08 CN CN201510354353.6A patent/CN105001225B/zh active Active
-
2013
- 2013-09-03 IL IL228276A patent/IL228276A/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06655A patent/ZA201306655B/en unknown
-
2016
- 2016-02-03 JP JP2016018610A patent/JP6061437B2/ja active Active
- 2016-02-03 JP JP2016018611A patent/JP2016074742A/ja active Pending
- 2016-04-11 HK HK16104111.8A patent/HK1216310A1/zh unknown
- 2016-09-13 IL IL247804A patent/IL247804B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200946B2 (en) | Modulators of the integrated stress pathway | |
| ES2708211T3 (es) | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas | |
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| JP2008535903A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| ES2624131T3 (es) | Moduladores heterocíclicos de la síntesis de lípidos | |
| JP2008535902A5 (enExample) | ||
| RU2013146659A (ru) | Способы лечения рака | |
| EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| JP2017533968A5 (enExample) | ||
| CN109641853A (zh) | 整合应激通路的调节剂 | |
| JP2011509949A5 (enExample) | ||
| PH12015502237A1 (en) | N- [ (2 ` r) -2 ` -deoxy-2 ` -fluoro-2 ` -methyl-p-phenyl-5 ` -uridylyl] -l-alanine 1-methylethyl ester and process for its production | |
| EA201290882A1 (ru) | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний | |
| EA200971074A1 (ru) | Антивирусные соединения | |
| EA201171386A1 (ru) | ПРОИЗВОДНЫЕ ЦИКЛОПЕНТА[c]ПИРРОЛ-2-КАРБОКСИЛАТОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2012528166A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2013543842A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| JP2016501223A5 (enExample) | ||
| JP2015500795A5 (enExample) | ||
| JP2011526917A5 (enExample) |